See how pharma brands have used the Rare Medical Network to drive disease awareness, physician engagement, and clinical readiness.
A pharma manufacturer with a first-to-market targeted treatment for APDS, an ultra-rare primary immunodeficiency, needed to find HCPs who may have undiagnosed APDS patients in their care. Multiple content formats were deployed to generate awareness and educate key physician specialties.
A biopharma company developing treatment for rare seizure disorders like LGS and TSC sought to increase new adult diagnoses. The challenge: low HCP awareness and difficulty reaching “no-see” providers through conventional outreach. The initiative focused on educating HCPs about adult diagnosis recognition.
APDS is a rare primary immunodeficiency first identified in 2013, making it unfamiliar to most HCPs. Rare Medical Network and Equals 5 collaborated on an integrated content marketing approach to identify and educate healthcare providers — measuring knowledge and interest impact.
A small biopharma launched a therapy for WHIM syndrome, an ultra-rare primary immunodeficiency. Because symptoms present to both hematologists and immunologists, both specialties needed education. With limited budgets, the company required an efficient way to identify and engage high-value HCP leads.